Nalee Kim1, Do Hoon Lim2, Sang Eun Yoon3, Seok Jin Kim3, Won Seog Kim3. 1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. 2. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. dh8lim@skku.edu. 3. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Abstract
INTRODUCTION: We aimed to investigate the role of upfront whole-brain radiation therapy (RT), with a reduced dose of 23.4 Gy, following high-dose methotrexate (HD-MTX) in patients with primary central nervous system lymphoma (PCNSL). METHODS: We retrospectively reviewed 185 patients with PCNSL treated with HD-MTX between January 2013 and January 2020; 145 patients underwent no RT and 40 patients underwent upfront RT. Using propensity score matching (PSM) to adjust for clinical factors, 40 patients were selected from each treatment group. Event-free survival (EFS) and overall survival (OS) were compared between treatment groups. RESULTS: At baseline, patients in the upfront RT group were younger, had higher LDH levels, received less frequent rituximab and stem cell transplantation than those in the no-RT group. Patients in the upfront RT group also showed a lower response rate after initial HD-MTX than those in the no-RT group (73% vs. 88%, p = 0.038). The median follow-up was 25.1 (interquartile range 13.7-43.0) months. Comparable 2-year EFS and OS rates were observed between the upfront RT and no-RT groups (56.6% vs. 53.8%, p = 0.170; and 81.7% vs. 75.3%, p = 0.097, respectively). Upfront RT was related to improved EFS and OS in patients with stable disease or progressive disease after HD-MTX, but not in patients with complete or partial response after HD-MTX. Upfront RT was also an independent predictor of EFS and OS in the PSM cohort. The cumulative incidences of treatment-related neurotoxicity at 3 years were 20.2% and 21.2% in the upfront RT and no-RT groups, respectively (p = 0.630). CONCLUSIONS: Upfront RT with a reduced dose of 23.4 Gy, showed favorable outcomes in patients with stable disease or progressive disease after initial HD-MTX. In addition, upfront RT appears to be an effective treatment for PCNSL when rituximab or stem cell transplantation is not feasible.
INTRODUCTION: We aimed to investigate the role of upfront whole-brain radiation therapy (RT), with a reduced dose of 23.4 Gy, following high-dose methotrexate (HD-MTX) in patients with primary central nervous system lymphoma (PCNSL). METHODS: We retrospectively reviewed 185 patients with PCNSL treated with HD-MTX between January 2013 and January 2020; 145 patients underwent no RT and 40 patients underwent upfront RT. Using propensity score matching (PSM) to adjust for clinical factors, 40 patients were selected from each treatment group. Event-free survival (EFS) and overall survival (OS) were compared between treatment groups. RESULTS: At baseline, patients in the upfront RT group were younger, had higher LDH levels, received less frequent rituximab and stem cell transplantation than those in the no-RT group. Patients in the upfront RT group also showed a lower response rate after initial HD-MTX than those in the no-RT group (73% vs. 88%, p = 0.038). The median follow-up was 25.1 (interquartile range 13.7-43.0) months. Comparable 2-year EFS and OS rates were observed between the upfront RT and no-RT groups (56.6% vs. 53.8%, p = 0.170; and 81.7% vs. 75.3%, p = 0.097, respectively). Upfront RT was related to improved EFS and OS in patients with stable disease or progressive disease after HD-MTX, but not in patients with complete or partial response after HD-MTX. Upfront RT was also an independent predictor of EFS and OS in the PSM cohort. The cumulative incidences of treatment-related neurotoxicity at 3 years were 20.2% and 21.2% in the upfront RT and no-RT groups, respectively (p = 0.630). CONCLUSIONS: Upfront RT with a reduced dose of 23.4 Gy, showed favorable outcomes in patients with stable disease or progressive disease after initial HD-MTX. In addition, upfront RT appears to be an effective treatment for PCNSL when rituximab or stem cell transplantation is not feasible.
Authors: Eckhard Thiel; Agnieszka Korfel; Peter Martus; Lothar Kanz; Frank Griesinger; Michael Rauch; Alexander Röth; Bernd Hertenstein; Theda von Toll; Thomas Hundsberger; Hans-Günther Mergenthaler; Malte Leithäuser; Tobias Birnbaum; Lars Fischer; Kristoph Jahnke; Ulrich Herrlinger; Ludwig Plasswilm; Thomas Nägele; Torsten Pietsch; Michael Bamberg; Michael Weller Journal: Lancet Oncol Date: 2010-10-20 Impact factor: 41.316
Authors: Patrick G Morris; Denise D Correa; Joachim Yahalom; Jeffrey J Raizer; David Schiff; Barbara Grant; Sean Grimm; Rose K Lai; Anne S Reiner; Kathy Panageas; Sasan Karimi; Richard Curry; Gaurav Shah; Lauren E Abrey; Lisa M DeAngelis; Antonio Omuro Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Gaurav D Shah; Joachim Yahalom; Denise D Correa; Rose K Lai; Jeffrey J Raizer; David Schiff; Renato LaRocca; Barbara Grant; Lisa M DeAngelis; Lauren E Abrey Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Christopher P Fox; Elisabeth Schorb; Paul La Rosée; Mascha Binder; Alberto Fabbri; Valter Torri; Eleonora Minacapelli; Monica Falautano; Fiorella Ilariucci; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Peter Johnson; Kim M Linton; Tobias Pukrop; Jette Sønderskov Gørløv; Monica Balzarotti; Georg Hess; Ulrich Keller; Stephan Stilgenbauer; Jens Panse; Alessandra Tucci; Lorella Orsucci; Francesco Pisani; Alessandro Levis; Stefan W Krause; Hans J Schmoll; Bernd Hertenstein; Mathias Rummel; Jeffery Smith; Michael Pfreundschuh; Giuseppina Cabras; Francesco Angrilli; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Jürgen Finke; Michele Reni; Franco Cavalli; Emanuele Zucca; Gerald Illerhaus Journal: Lancet Haematol Date: 2017-10-17 Impact factor: 18.959